Journal of Clinical Endocrinology & Metabolism, Vol 78, 1403-1410, Copyright © 1994 by Endocrine Society

ARTICLES

Persistence of rapid growth hormone (GH) pulsatility after successful removal of GH-producing pituitary tumors

PJ Ho, CA Jaffe, RD Friberg, WF Chandler and AL Barkan
Division of Endocrinology and Metabolism, Department of Veterans Affairs Medical Center, Ann Arbor, Michigan 48109.

GH concentration profiles in patients with acromegaly are characterized by rapid GH pulsatility and high interpulse GH concentrations. Animal and human studies have shown that GH pulses are consequent upon periodic discharges of hypothalamic GHRH, whereas interpulse GH levels might reflect tonic secretion of hypothalamic SRIH. Thus, the pattern of GH secretion in acromegaly may conceivably be attributed to high GHRH pulse frequency and/or SRIH deficiency. If this assumption is correct, removal of a GH-producing tumor should be followed by a persistently high GH pulse frequency and a high recurrence rate. We have studied pulsatile GH secretion in 12 patients with acromegaly before and after apparently complete removal of their pituitary tumors. Despite normalization of GH secretion after surgery, the disease recurred in 3 patients within 3 yr. The other 9 patients had normal insulin-like growth factor-I and basal and dynamic GH concentrations for 24 +/- 4 months postsurgery. Parameters of GH secretion in this group (pre- and postsurgery) were compared to sex-, age-, and body mass index-matched controls. Plasma GH concentrations in the postoperative and control series were analyzed by a chemiluminescent assay with a sensitivity of 0.01 micrograms/L. Removal of the somatotroph tumor led to normalization of mean and interpulse (but not the nadir) GH levels, pulse amplitude, and responses to GHRH. However, GH pulse frequency (14.2 +/- 1.2 vs. 11.8 +/- 0.9 pulses/24 h) did not change and was significantly (P < 0.001) higher than the control value (8.7 +/- 0.9 pulses/24 h). Thus, SRIH secretion in acromegaly is not inherently deficient, and high interpulse GH levels reflect the mass of tumorous somatotrophs. The persistence of rapid GH pulsatility in apparently "cured" patients with acromegaly suggests that abnormally rapid GHRH pulsatility may be an inherent component of the disease process.

This article has been cited by other articles:

				A. Bianchi, A. Giustina, V. Cimino, R. Pola, F. Angelini, A. Pontecorvi, and L. De Marinis Influence of Growth Hormone Receptor d3 and Full-Length Isoforms on Biochemical Treatment Outcomes in Acromegaly J. Clin. Endocrinol. Metab., June 1, 2009; 94(6): 2015 - 2022. [Abstract] [Full Text] [PDF]

				K. Bajuk Studen and A. Barkan Assessment of the Magnitude of Growth Hormone Hypersecretion in Active Acromegaly: Reliability of Different Sampling Models J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 491 - 496. [Abstract] [Full Text] [PDF]

				E. V. Dimaraki, W. F. Chandler, M. B. Brown, C. A. Jaffe, S. Y. Kim, R. Taussig, V. Padmanabhan, and A. L. Barkan The Role of Endogenous Growth Hormone-Releasing Hormone in Acromegaly J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2185 - 2190. [Abstract] [Full Text] [PDF]

				J. Ayuk, R. N. Clayton, G. Holder, M. C. Sheppard, P. M. Stewart, and A. S. Bates Growth Hormone and Pituitary Radiotherapy, But Not Serum Insulin-Like Growth Factor-I Concentrations, Predict Excess Mortality in Patients with Acromegaly J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1613 - 1617. [Abstract] [Full Text] [PDF]

				P. U. Freda, A. T. Nuruzzaman, C. M. Reyes, R. E. Sundeen, and K. D. Post Significance of "Abnormal" Nadir Growth Hormone Levels after Oral Glucose in Postoperative Patients with Acromegaly in Remission with Normal Insulin-Like Growth Factor-I Levels J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 495 - 500. [Abstract] [Full Text] [PDF]

				N. R. Biermasz, A. M. Pereira, M. Frolich, J. A. Romijn, J. D. Veldhuis, and F. Roelfsema Octreotide represses secretory-burst mass and nonpulsatile secretion but does not restore event frequency or orderly GH secretion in acromegaly Am J Physiol Endocrinol Metab, January 1, 2004; 286(1): E25 - E30. [Abstract] [Full Text]

				D. R. Clemmons, K. Chihara, P. U. Freda, K. K. Y. Ho, A. Klibanski, S. Melmed, S. M. Shalet, C. J. Strasburger, P. J. Trainer, and M. O. Thorner Optimizing Control of Acromegaly: Integrating a Growth Hormone Receptor Antagonist into the Treatment Algorithm J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4759 - 4767. [Abstract] [Full Text] [PDF]

				E. V. Dimaraki, C. A. Jaffe, R. DeMott-Friberg, W. F. Chandler, and A. L. Barkan Acromegaly with Apparently Normal GH Secretion: Implications for Diagnosis and Follow-Up J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3537 - 3542. [Abstract] [Full Text] [PDF]

				S. R. Peacey, A. A. Toogood, J. D. Veldhuis, M. O. Thorner, and S. M. Shalet The Relationship between 24-Hour Growth Hormone Secretion and Insulin-Like Growth Factor I in Patients with Successfully Treated Acromegaly: Impact of Surgery or Radiotherapy J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 259 - 266. [Abstract] [Full Text]

				R. G. Veldman, M. Frölich, S. M. Pincus, J. D. Veldhuis, and F. Roelfsema Apparently Complete Restoration of Normal Daily Adrenocorticotropin, Cortisol, Growth Hormone, and Prolactin Secretory Dynamics in Adults with Cushing's Disease after Clinically Successful Transsphenoidal Adenomectomy J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4039 - 4046. [Abstract] [Full Text]

				H.E. Turner and J.A.H. Wass Modern approaches to treating acromegaly QJM, January 1, 2000; 93(1): 1 - 6. [Full Text] [PDF]

				P. U. Freda, K. D. Post, J. S. Powell, and S. L. Wardlaw Evaluation of Disease Status with Sensitive Measures of Growth Hormone Secretion in 60 Postoperative Patients with Acromegaly J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 3808 - 3816. [Abstract] [Full Text]

				S. M. Orme, R. J. Q. McNally, R. A. Cartwright, and P. E. Belchetz Mortality and Cancer Incidence in Acromegaly: A Retrospective Cohort Study J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2730 - 2734. [Abstract] [Full Text]

				S. R. Peacey, A. A. Toogood, and S. M. Shalet Hypothalamic Dysfunction in "Cured" Acromegaly Is Treatment Modality Dependent J. Clin. Endocrinol. Metab., May 1, 1998; 83(5): 1682 - 1686. [Abstract] [Full Text]

				A. L. Barkan, I. Halasz, K. J. Dornfeld, C. A. Jaffe, R. D. Friberg, W. F. Chandler, and H. M. Sandler Pituitary Irradiation Is Ineffective in Normalizing Plasma Insulin-Like Growth Factor I in Patients with Acromegaly J. Clin. Endocrinol. Metab., October 1, 1997; 82(10): 3187 - 3191. [Abstract] [Full Text] [PDF]

				C. A. Jaffe, R. DeMott-Friberg, L. A. Frohman, and A. L. Barkan Suppression of Growth Hormone (GH) Hypersecretion due to Ectopic GH-Releasing Hormone (GHRH) by a Selective GHRH Antagonist J. Clin. Endocrinol. Metab., February 1, 1997; 82(2): 634 - 637. [Abstract] [Full Text] [PDF]